136 related articles for article (PubMed ID: 37804738)
1. Increased risk of venous and arterial thromboembolism in patients with colorectal cancer receiving cetuximab-based combination chemotherapy: A population-based study in Korea.
Yhim HY; Lee J; Kim KH; Kim SA; Lee JY; Hwang HG; Hong J; Lee JO; Bang SM
Thromb Res; 2023 Nov; 231():50-57. PubMed ID: 37804738
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Riedl JM; Schwarzenbacher E; Moik F; Horvath L; Gantschnigg A; Renneberg F; Posch F; Barth DA; Stotz M; Pichler M; Hatzl S; Fandler-Höfler S; Gressenberger P; Gary T; Jost PJ; Greil R; Ay C; Djanani A; Gerger A; Schlick K
Thromb Haemost; 2022 Apr; 122(4):633-645. PubMed ID: 34255340
[TBL] [Abstract][Full Text] [Related]
3. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study.
Lee I; Adimadhyam S; Nutescu EA; Zhou J; Asfaw AA; Sweiss KI; Patel PR; Calip GS
Pharmacotherapy; 2019 Sep; 39(9):921-928. PubMed ID: 31332810
[TBL] [Abstract][Full Text] [Related]
5. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
Patel JN; Jiang C; Hertz DL; Mulkey FA; Owzar K; Halabi S; Ratain MJ; Friedman PN; Small EJ; Carducci MA; Mahoney JF; Kelley MJ; Morris MJ; Kelly WK; McLeod HL
Cancer; 2015 Apr; 121(7):1025-31. PubMed ID: 25417775
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.
Lv ZC; Ning JY; Chen HB
Tumour Biol; 2014 Dec; 35(12):11741-50. PubMed ID: 25417200
[TBL] [Abstract][Full Text] [Related]
10. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.
Zhou SW; Huang YY; Wei Y; Jiang ZM; Zhang YD; Yang Q; Xie DR
PLoS One; 2012; 7(11):e50925. PubMed ID: 23226426
[TBL] [Abstract][Full Text] [Related]
11. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Scappaticci FA; Skillings JR; Holden SN; Gerber HP; Miller K; Kabbinavar F; Bergsland E; Ngai J; Holmgren E; Wang J; Hurwitz H
J Natl Cancer Inst; 2007 Aug; 99(16):1232-9. PubMed ID: 17686822
[TBL] [Abstract][Full Text] [Related]
12. Venous and arterial thromboembolism after colorectal cancer in the Netherlands: Incidence, predictors, and prognosis.
Anijs RJS; Chen Q; van der Hulle T; Versteeg HH; Klok FA; Lijfering WM; Cannegieter SC
Thromb Res; 2023 Sep; 229():90-98. PubMed ID: 37421683
[TBL] [Abstract][Full Text] [Related]
13. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis.
Golfinopoulos V; Salanti G; Pavlidis N; Ioannidis JP
Lancet Oncol; 2007 Oct; 8(10):898-911. PubMed ID: 17888735
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
Nakamoto Y; Noda M; Mikami R; Tokunaga Y; Okumoto T; Kawamura T; Fujiwara H; Doi S; Tomita N
Int J Clin Oncol; 2020 Jul; 25(7):1285-1290. PubMed ID: 32200481
[TBL] [Abstract][Full Text] [Related]
15. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of arterial thrombotic events after unprovoked venous thromboembolism, and after cancer associated venous thromboembolism: A prospective cohort study.
Noumegni SR; Didier R; Mansourati V; Tromeur C; Le Moigne E; Hoffmann C; Nasr B; Gentric JC; Guegan M; Poulhazan E; Lacut K; Bressollette L; Le Mao R; Couturaud F
Thromb Res; 2022 Jun; 214():93-105. PubMed ID: 35525202
[TBL] [Abstract][Full Text] [Related]
17. Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.
Bamias A; Tzannis K; Dimitriadis I; Tsironis G; Papatheorodidi AM; Tsiara A; Fragkoulis C; Xirokosta A; Barbarousi D; Papadopoulos G; Zakopoulou R; Varkarakis I; Mitsogiannis I; Adamakis I; Alamanis C; Stravodimos K; Papatsoris AG; Dellis AE; Drivalos A; Ntoumas K; Matsouka H; Halvatsiotis P; Raptis A; Gerotziafas GT; Dimopoulos MA
Clin Genitourin Cancer; 2020 Aug; 18(4):e457-e472. PubMed ID: 32007440
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Shitara K; Yuki S; Yoshida M; Takahari D; Utsunomiya S; Yokota T; Sato Y; Inaba Y; Tajika M; Kawai H; Yamaura H; Kato M; Yamazaki K; Komatsu Y; Muro K
Invest New Drugs; 2012 Apr; 30(2):787-93. PubMed ID: 21174225
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
Tanioka H; Shimada K; Tsuji A; Kochi M; Kim HM; Takahashi T; Denda T; Takagane A; Watanabe T; Kotaka M; Nakamura M; Sunakawa YU; Takeuchi M; Ichikawa W; Fujii M
Anticancer Res; 2022 May; 42(5):2675-2681. PubMed ID: 35489740
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.
Garrett CR; Bekaii-Saab TS; Ryan T; Fisher GA; Clive S; Kavan P; Shacham-Shmueli E; Buchbinder A; Goldberg RM
Cancer; 2013 Dec; 119(24):4223-30. PubMed ID: 24105075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
